EP4051147A1 - Modulation de l'apport d'énergie de dénervation rénale - Google Patents

Modulation de l'apport d'énergie de dénervation rénale

Info

Publication number
EP4051147A1
EP4051147A1 EP20811201.1A EP20811201A EP4051147A1 EP 4051147 A1 EP4051147 A1 EP 4051147A1 EP 20811201 A EP20811201 A EP 20811201A EP 4051147 A1 EP4051147 A1 EP 4051147A1
Authority
EP
European Patent Office
Prior art keywords
energy
temperature
treatment site
amount
therapeutic assembly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20811201.1A
Other languages
German (de)
English (en)
Inventor
Paul Coates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Ireland Manufacturing ULC
Original Assignee
Medtronic Ardian Luxembourg SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Ardian Luxembourg SARL filed Critical Medtronic Ardian Luxembourg SARL
Publication of EP4051147A1 publication Critical patent/EP4051147A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/1206—Generators therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345—Vascular system
    • A61B2018/00404—Blood vessels other than those in or around the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00577—Ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00642—Sensing and controlling the application of energy with feedback, i.e. closed loop control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00642—Sensing and controlling the application of energy with feedback, i.e. closed loop control
    • A61B2018/00654—Sensing and controlling the application of energy with feedback, i.e. closed loop control with individual control of each of a plurality of energy emitting elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00666—Sensing and controlling the application of energy using a threshold value
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00696—Controlled or regulated parameters
    • A61B2018/00702—Power or energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00791—Temperature

Definitions

  • the subject matter is embodied in a therapeutic assembly for renal denervation.
  • the therapeutic assembly includes a first electrode configured to deliver energy to a treatment site.
  • the therapeutic assembly includes a first temperature sensor coupled to the first electrode and configured to measure a first temperature of the first electrode.
  • the therapeutic assembly includes a processor coupled to the first temperature sensor and the first electrode. The processor is configured to increase the delivery of energy to the treatment site when the first temperature is less than or equal to a first threshold temperature and decrease the delivery of energy to the treatment site when the first temperature is greater than or equal to a second threshold temperature.
  • a renal denervation device delivers a constant amount of energy to the one or more energy delivery elements, but due to the changes in blood flow, the temperature at the treatment site will oscillate between a minimum and maximum temperature. This may cause the renal denervation device to inadvertently cause damage to the wall of the blood vessel when the temperature becomes too high and/or not effectively innervate the nerves when the temperature becomes too low.
  • the energy modulating renal denervation device (“renal denervation device”) has one or more integrated sensors that measure the temperature of the energy delivery element positioned on the wall of the vessel and/or the temperature at the treatment site at a location on the wall of the vessel, such as the renal artery.
  • the renal denervation device may monitor different aspects of the temperature including an average temperature, a minimum and/or a maximum temperature and the frequency of the cycles of the temperature between the minimum and/or the maximum temperature.
  • the heartbeat may be determined using an additional device that supplies energy or power at a constant rate to cause a measurable increase in the temperature so that the heart rate may be determined based on the oscillation of the temperature.
  • the additional device may have a sensor that measures the temperature. The power, energy or temperature increase would be selected low enough so as to not cause any change to any tissue with which the additional device contacts and may be designed to ensure that the additional device does not contact the vessel wall.
  • the renal denervation device may have multiple energy delivery elements that are positioned at different locations within or along the wall of the vessel.
  • the renal denervation device may control the delivery of energy through each of the one or more energy delivery elements independently to manage the temperature of tissue at the treatment site.
  • the renal denervation device may measure and control the amount of energy delivered in real-time to mitigate temperature oscillations due to changes in blood flow.
  • the temperature at the treatment site and/or the electrode will vary during systole and diastole due to the difference in blood flow.
  • the temperature drops during systole because a wave of cooling blood is pushed down the renal artery and rises during diastole because the blood flow slows.
  • the renal denervation device may increase energy delivery during systole and decrease energy delivery during diastole to reduce the temperature oscillation.
  • modulation of the energy reduces temperature peaks that occur as a result of changes in blood flow when the heart beats, which minimizes damage to the blood vessel while ensuring sufficient temperature to modulate the nerves per the requirements of the renal denervation device.
  • FIG. 1 shows the therapeutic assembly 100.
  • the therapeutic assembly 100 performs renal denervation within the renal artery of a human patient. Renal denervation is a minimally invasive procedure to treat resistant hypertension.
  • the therapeutic assembly 100 includes a renal denervation device 102 and/or a generator 104.
  • the renal denervation device 102 may include any device that delivers energy or stimulus to a target nerve within a wall of a blood vessel, such as the renal nerve of the renal artery.
  • the energy or stimulus may include, for example, at least one of a radio frequency stimulus, a thermal stimulus, a cryogenic stimulus, a microwave stimulus, an ultrasonic stimulus or other form of energy or stimulus. Regardless of the type of energy delivered, the renal denervation device 102 does not fully occlude the blood vessel, and thus, blood may continue to flow through the blood vessel.
  • the renal denervation device 102 has a catheter 108, one or more energy delivery elements 110, such as an electrode, and/or one or more sensors 112, such as a temperature sensor.
  • the renal denervation device 102 may have an elongated shaft 114 with a handle 116.
  • the elongated shaft 114 with the handle 116 may be used to guide and/or advance a distal portion of the catheter 108 through the blood vessels of the patient, such as a human patient, to a target location of a blood vessel and remotely manipulate the distal portion of the catheter 108.
  • the catheter 108 may be intravascularly delivered into the patient, e.g., a blood vessel of the patient, in a low-profile configuration, such as the substantially straight configuration shown in FIG. 1.
  • the catheter 108 may have a distal tip 202.
  • the distal tip 202 points into the lumen of the blood vessel.
  • the distal tip 202 may have a high density marker band 204.
  • the high density marker band 204 allows a clinician to identify the distal tip 202 of the catheter 108 under fluoroscopy.
  • the distal portion of the catheter 108 may be approximately 4 cm - 5 cm in length, and the distal tip 202 may be approximately 1 cm - 2 cm in length.
  • the renal denervation device 102 has one or more energy delivery elements 110.
  • the one or more energy delivery elements 110 may include an electrode, such as a radiofrequency electrode, a radiofrequency probe, a thermal probe, a cryogenic probe, a microwave probe, an ultrasonic probe, an optical source or a chemical injector.
  • the one or more energy delivery elements 110 may deliver and/or provide neuromodulation energy, such as radiofrequency energy, thermal energy, microwave energy, ultrasound energy or other neuromodulation energy, to ablate nerves at or around a treatment site located on a wall of the blood vessel.
  • the one or more energy delivery elements 110 may be positioned on the distal portion of the catheter 108.
  • the energy delivery elements 110 may be spaced any suitable distance from each other, and the spacing may vary based on the application of the therapeutic assembly 100 and its intended use.
  • a first energy delivery element 110a may contact the wall of the blood vessel 304 at a first location 302a
  • a second energy delivery element 110b may contact the wall of the blood vessel 304 at a second location 302b
  • a third energy delivery element 110c may contact the wall of the blood vessel 304 at a third location 302c
  • a fourth energy delivery element 110d may contact the wall of the blood vessel 304 at a fourth location 302d.
  • the renal denervation device 102 may deliver energy through the one or more energy delivery elements 110 at the treatment site and provide therapeutically-effective electrically- and/or thermally- induced denervation.
  • the renal denervation device 102 includes one or more sensors 112.
  • the one or more sensors 112 may be a temperature sensor that measures the temperature at a location of the wall of the blood vessel.
  • the temperature may be the temperature of the one or more energy delivery elements 110 at the location of the wall of the blood vessel and/or the temperature at the treatment site.
  • the temperature may be used to interpolate the heart rate of the patient.
  • Each of the one or more sensors 112 may be coupled to, integrated with or in a close proximity to a corresponding one of the one or more energy delivery elements 110. This allows each of the one or more sensors
  • the first sensor 112a may be integrated with the first energy delivery element 110a
  • the second sensor 112b may be integrated with second energy delivery element 110b
  • the third sensor 112c may be integrated with the third energy delivery element 110c
  • the fourth sensor 112d may be integrated with the fourth energy delivery element 110d, as shown in FIG. 2B for example.
  • the generator 104 may have multiple separate channels, such as four RF channels to deliver RF energy independently to the energy delivery elements 110a-d and control and monitor each energy delivery element 110a-d independently.
  • the generator 104 may generate energy that ultimately is transmitted through the electrical lead to the one or more energy delivery elements 110.
  • the generator 104 may have a memory 404.
  • the memory may be coupled to the one or more processors 402 and store instructions that the one or more processors 402 executes.
  • the memory 404 may include one or more of a Random Access Memory (RAM), Read Only Memory
  • the memory 404 may be a non-transitory memory or a data storage device, such as a hard disk drive, a solid-state disk drive, a hybrid disk drive, or other appropriate data storage, and may further store machine-readable instructions, which may be loaded and executed by the one or more processors 402.
  • the memory 404 may store one or more thresholds and/or one or more normal temperature parameter values that relate to the temperature of the one or more energy delivery elements 110 at the treatment site.
  • the generator 104 may have a power source 408, such as a RF generator or other electrical source.
  • the power source 408 provides a selected form and magnitude of energy for delivery to the treatment site via the renal denervation device 102.
  • the generator 104 may have a user interface 118, The generator 104 may receive input, such as the selected form and the magnitude of energy to be delivered to each of the one or more energy delivery elements 110, via the user interface 118.
  • the user interface 118 may include an input/output device that receives user input from a user interface element, a button, a dial, a microphone, a keyboard, or a touch screen.
  • the user interface 118 may provide an output to an output device, such as a display, a speaker, an audio and/or visual indicator, or a refreshable braille display.
  • the output device may display an alert or notification or other information to the clinician and/or to confirm status and/or commands from the clinician.
  • the output device may be an audio output device that outputs an audio indicator that indicates the notification or information to be provided to the clinician.
  • FIG. 5 is a flow diagram of a process 500 for controlling the energy delivered to the one or more energy delivery elements 110 to prevent thermal damage to the tissues of the blood vessel.
  • One or more computers or one or more data processing apparatuses for example, the processor 402 of the therapeutic assembly 100 of FIG. 1, appropriately programmed, may implement the process 500.
  • the therapeutic assembly 100 may include a generator 104, which controls the delivery of energy to the one or more energy delivery elements 110 of the renal denervation device 102.
  • the generator 104 of the therapeutic assembly 100 receives user input that indicates initialization of the renal denervation device 102 (502).
  • the generator 104 may receive the user input, which may be an indication to power-on the generator 104, via the user interface 118, which causes the generator 104 to power-on or initialize to deliver energy to the renal denervation device 102 and through the one or more energy delivery elements 110 to the wall of the blood vessel 304.
  • the therapeutic assembly 100 may obtain or determine one or more threshold temperature values (504).
  • the therapeutic assembly 100 may obtain the one or more threshold temperature values from the memory 404.
  • the one or more threshold temperature values may be user-configured, pre-configured or from a previous measurement or treatment session with the patient.
  • the therapeutic assembly 100 determines the one or more threshold temperature values by measuring the temperature over a time period prior to delivery of the energy to the one or more energy delivery elements 110 when beginning treatment.
  • the one or more threshold temperature values may include a threshold shutoff temperature of the one or more energy delivery elements 110.
  • the threshold shutoff temperature may be used as an indicator to turn off, disable or otherwise power off all of the one or more energy delivery elements 110 to prevent thermal damage to the blood vessel.
  • the one or more threshold temperature values may include one or more normal thresholds.
  • the one or more normal thresholds may be a range that indicates an average or historically normal range of a corresponding temperature parameter of the patient when there is no stimulation or energy being delivered.
  • the one or more normal thresholds may be the frequency, magnitude and/or amplitude of the oscillation of the temperature during a time period.
  • the one or more normal thresholds may be a range for the average, minimum and/or maximum temperature value of the patient.
  • one or more normal thresholds may be determined for the temperature of each individual energy delivery element 110 at the various locations within the blood vessel of the patient.
  • the therapeutic assembly 100 may deliver a first amount of energy through the one or more energy delivery elements 110 (506).
  • the generator 104 may linearly or non-linearly ramp up or increase the amount of energy to the first amount of energy during the start-up phase until the amount of energy reaches the first amount of energy, such as approximately
  • the generator 104 may deliver the first amount of energy to each of the multiple energy delivery elements 110a-b when there are multiple energy delivery elements 110a-b.
  • the multiple energy delivery elements 110a-d may be arranged to contact the wall of the blood vessel at approximately 90 degree angles relative to a longitudinal axis that runs through the center of the spiral or helical configuration when there are four energy delivery elements 110a-d and the catheter 108 is in the expanded deployed state within the blood vessel, as shown in FIG. 3 for example.
  • the energy delivery elements 110 may depend on the number of energy delivery elements 110. For example, when there are only three energy delivery elements 110, the energy delivery elements 110 may be arranged at approximately 120 degree angles.
  • the therapeutic assembly 100 measures, detects, obtins or determines the temperature at the treatment site (508).
  • the temperature may indicate a temperature of the one or more energy delivery elements 110, which relates to a temperature at the location of the placement of the one or more energy delivery elements 110 along the wall of the blood vessel. This provides an indication of the temperature of a region of tissue within the wall of the blood vessel.
  • the therapeutic assembly 100 may use the one or more sensors 112 to measure the temperature at the treatment site along the wall of the blood vessel. For example, the therapeutic assembly 100 may measure the voltage change across a voltage gap between two wires within an energy delivery element to determine the temperature.
  • the one or more sensors 112 may include multiple temperature sensors each positioned within a corresponding energy delivery element 110. Each of the multiple temperature sensors may independently measure the temperature at the corresponding location along the wall of the blood vessel 304 that is in contact with the temperature sensor.
  • the first energy delivery element 110a may be coupled with a first sensor 112a at a first location 302a along the blood vessel 304 and the second energy delivery element 110b may be coupled with a second sensor 112b at a second location 302b along the blood vessel 304.
  • Other energy delivery elements 110c-d may be coupled with other sensors 112c-d at other locations 302c-d, respectively, along the blood vessel 304.
  • the first sensor 112a may measure a first temperature 702a, as shown in FIG.
  • the second sensor 112b may measure a second temperature 702b of the second energy delivery element 110b at the second location 302b
  • the third sensor 112c may measure a third temperature 702c of the third energy delivery element 110c at the third location 302c
  • the fourth sensor 112d may measure a fourth temperature 702d of the fourth energy delivery element 110d at the fourth location 302d.
  • 110 may be used to compute the temperature at any number of locations.
  • the temperature at each of the multiple temperature sensors may be an instantaneous temperature and/or the temperature over a time period.
  • the therapeutic assembly may measure or determine the temperatures using each of the multiple temperature sensors and form an aggregated temperature.
  • the aggregate temperature may be the instantaneous temperature or the average temperature over the time period.
  • the average temperature may also refer to an exponential moving average or other weighted average.
  • the therapeutic assembly 100 may determine different parameters from the temperature, such as a minimum temperature 704, a maximum temperature 706, an average temperature, a frequency of oscillation 708 or other parameter of the temperature from a single sensor coupled to a single energy delivery element or from an aggregation of the multiple sensors coupled the multiple energy delivery elements 110.
  • the therapeutic assembly 100 determines whether the temperature is greater than or equal to a threshold temperature (510).
  • the threshold temperature may be a threshold shutoff temperature, which may be approximately be between 80 °C - 100 °C.
  • the volume of tissue that is exposed to the thermally damaging temperature which may be as low as 45 °C, may also increase. This results in a greater probability that non-target tissue will suffer irreparable damage.
  • the therapeutic assembly 100 compares the temperature to the threshold shutoff temperature. When the temperature is greater or equal to the threshold shutoff temperature, this may indicate there may be thermal damage to non-target tissues. And, the therapeutic assembly
  • the 100 may shut off, turn off, or otherwise disable the delivery of energy to the treatment site via the one or more energy delivery elements 110 (512).
  • the therapeutic assembly 100 shuts down due to hitting the threshold shutoff temperature and stops power delivery to all the energy delivery elements 110. By shutting off the delivery of energy to the treatment site, this prevents, minimizes or reduces thermal damage to the tissues of and surrounding the blood vessel including non-target tissue surrounding the blood vessel.
  • the therapeutic assembly may continue to monitor any abnormalities in the temperature and may determine whether the temperature exceeds one or more normal threshold values (514).
  • the one or more abnormalities may include a temperature oscillation that exceeds a normal frequency, amplitude and/or magnitude.
  • FIG. 6 further describes the process of determining whether the temperature exceeds one or more normal threshold values.
  • the therapeutic assembly 100 controls, adjusts or otherwise modulates the amount of energy delivered to the treatment site to prevent thermal damage to the non-target tissue while maintaining effective treatment of the nerves.
  • the therapeutic assembly 100 may control, adjust or otherwise modulate the amount of energy delivered to the treatment site to a second amount of energy.
  • the second amount of energy may be different that the first amount of energy that was delivered prior to the adjustment of the delivery of the energy.
  • the therapeutic assembly 100 may adjust the energy at a frequency of at least 5 Hz.
  • the therapeutic assembly 100 may maintain the energy between approximately 6 W and 7 W, such as to maintain an average of 6.5 W, and synchronize the adjustment of the energy with the blood flow and/or heartbeat to minimize but not eliminate the temperature oscillation that occurs due to blood flow within the blood vessel during systole and diastole.
  • the second amount of energy may be a lower amount of energy of approximately 6 W, which may be delivered at the peak of diastole when the temperature is greater than or equal to a threshold temperature
  • the second amount of energy may be a higher amount of energy of approximately 7 W, which may be delivered at the peak of systole when the temperature is less than or equal to a threshold temperature. This would modulate the temperature and may reduce the number of incidences of shutoff of the therapeutic assembly 100.
  • the therapeutic assembly 100 may control, adjust or otherwise modulate the amount of energy delivered to the treatment site in the aggregate by multiple energy delivery elements 110 based on the temperature aggregated and/or averaged from the multiple sensors 112. For example, the therapeutic assembly 100 may control a total amount of energy delivered by the multiple energy delivery elements 110a-d based on the average of all the temperatures aggregated from the sensors 112a-d.
  • the therapeutic assembly 100 may control, adjust or otherwise modulate the amount of energy delivered to the treatment site by each individual multiple energy delivery element 110a-d.
  • the therapeutic assembly 100 may increase or decrease the amount of energy delivered by the first energy delivery element 110a based on the temperature from the first sensor 112a, and simultaneously, may increase or decrease the amount of energy delivered by the second energy delivery element 110b based on the temperature from the second sensor 112b.
  • the therapeutic assembly 100 may first control a total amount of energy delivered by multiple energy delivery elements 110 to partially stabilize the oscillation of the temperature, and then, control the amount of energy delivered by each individual energy delivery element 110 to further stabilize the temperature with a greater degree of fidelity.
  • the therapeutic assembly 100 may increase the amount of energy delivered if the energy delivery element 110 has poor contact, such as when less than approximately 25% of the surface area of the energy delivery element 110 is in contact, with the vessel wall. Conversely, the therapeutic assembly 100 may decrease the amount of energy delivered if the energy delivery element has sufficient contact, such as when more than approximately 75% of the surface area of the energy delivery element 110 is in contact, with the vessel wall.
  • the therapeutic assembly 100 delivers or provides the energy to the treatment site (518). Before, during and/or after the delivery of the energy to the treatment site, the therapeutic assembly 100 may continue to monitor, measure, obtain and/or determine the temperature at the treatment site
  • the therapeutic assembly 100 may not continue to monitor, measure, obtain and/or determine the temperature at the treatment site after the delivery of the energy to the treatment site.
  • FIG. 6 is a flow diagram of a process 600 for adjusting the amount of energy delivered to the one or more energy delivery elements 110 to minimize or reduce temperature oscillation of the one or more energy delivery elements 110 and/or at the treatment sites along the wall of the blood vessel.
  • One or more computers or one or more data processing apparatuses for example, the processor 402 of the therapeutic assembly 100 of FIG. 1, appropriately programmed, may implement the process 600.
  • the therapeutic assembly 100 adjusts the amount of energy delivered to compensate for the fluctuation in temperature to minimize, but not necessarily eliminate, oscillation so that thermal damage to the tissues of the blood vessel is prevented, such as when the temperature is at a maximum, and effective treatment of the nerves continues, such as when the temperature is at a minimum.
  • the oscillation may be eliminated when there is an additional device to measure the heart rate.
  • the therapeutic assembly 100 determines the temperature at the treatment site along the wall of the blood vessel, as described above (602).
  • the therapeutic assembly 100 may determine the temperature of the energy delivery element 110 and/or the temperature at the treatment site.
  • the temperature at the treatment site reflects or corresponds to the movement of the blood flow within the blood vessel, and thus, may be reflective or correspond to the systole or diastole phases of the heartbeat and/or the heart rate.
  • the therapeutic assembly 100 calculates or determines one or more temperature parameters based on the temperature (604).
  • the one or more temperature parameters may be an instantaneous measurement or a measurement over a time period of a single energy delivery element 110a-d or multiple energy delivery elements 110a-d.
  • the one or more temperature parameters may be a minimum, a maximum, or calculation made from the temperature.
  • the one or more temperature parameters that may be calculated include the average temperature, an exponential moving average, a rate of change in the temperature and/or a frequency, amplitude and/or magnitude of the oscillation of the temperature over a time period.
  • the therapeutic assembly 100 continues to monitor or determine the temperature of the one or more energy delivery elements 110 at the corresponding treatment sites (602).
  • the therapeutic assembly 100 determines whether the temperature is less than or equal to a low threshold temperature, such as during systole when the temperature is likely at a minimum (608).
  • the low threshold temperature may be in a range of approximately 35 °C - 45 °C.
  • the one or more energy delivery elements 110 may not be delivering enough energy to the location at the wall of the blood vessel to effectively innervate the nerves.
  • the therapeutic assembly 100 increases energy delivered through the one or more energy delivery elements 110 (610).
  • the therapeutic assembly 100 may increase the energy delivered from a first amount of energy to a second amount of energy that is greater than the first amount of energy.
  • the second amount of energy may be a fixed amount or a variable amount.
  • the variable amount may be based on the difference between the temperature and the low threshold temperature, as further described below.
  • the therapeutic assembly 100 may increase the energy delivered through some of, all of, or a single one of the energy delivery elements 110. In some implementations, the therapeutic assembly 100 may increase the energy delivered to all of the one or more energy delivery elements
  • the therapeutic assembly 100 may further identify the one or more energy delivery elements 110 that have corresponding temperatures that are below the temperatures of the other energy delivery elements 110 and further increase or adjust the amount of energy delivered through the identified one or more energy delivery elements 110.
  • the therapeutic assembly 100 may monitor, obtain, detect or determine the temperature before, during and/or after the therapeutic assembly 100 increases the energy delivered through the one or more energy delivery elements 110. And, the therapeutic assembly 100 may increase the amount of energy delivered to the one or more energy delivery elements 110 until the aggregate temperature and/or the temperature at each individual energy delivery element is greater than the low threshold temperature. This facilitates delivery of energy to effectively innervate the nerves.
  • the therapeutic assembly 100 determines whether the temperature is greater than or equal to a high threshold temperature, such as during diastole when the temperature is likely at a maximum (612).
  • the high threshold temperature may be in a range of approximately 55° C - 65° C.
  • the therapeutic assembly 100 continues to monitor and determine the temperature of the energy delivery elements 110 at the treatment sites (602). Otherwise, when the temperature is above the high threshold temperature, the therapeutic assembly 100 may be causing thermal damage to the tissues within the wall of the blood vessel and/or other tissues surrounding the blood vessel including non-target tissue. .
  • the therapeutic assembly 100 may decrease the energy delivered to the one or more energy delivery elements 110 to prevent thermal damage to the tissues (614).
  • the therapeutic assembly 100 may decrease the energy delivered from a first amount of energy to a third amount of energy that is less than the first amount of energy.
  • the third amount of energy may be a fixed amount or a variable amount.
  • the variable amount may be based on the difference between the temperature and the high threshold temperature, as further described below.
  • the therapeutic assembly 100 may decrease the energy delivered to some of, all of, or a single one of the energy delivery elements 110. In some implementations, the therapeutic assembly 100 may decrease the energy delivered to all of the one or more energy delivery elements
  • the therapeutic assembly 100 may further identify the one or more energy delivery elements 110 that have corresponding temperatures that are above the temperatures of the other energy delivery elements 110 and further decrease or adjust the amount of energy delivered through the identified one or more energy delivery elements 110.
  • the therapeutic assembly 100 may monitor, detect and/or determine the temperature before, during and/or after the therapeutic assembly 100 decreases the energy delivered through the one or more energy delivery elements
  • the therapeutic assembly 100 may decrease the amount of energy delivered to the one or more energy deliveiy elements 110 until the aggregate temperature and/or the temperature at each individual energy delivery element is less than the high threshold temperature.
  • the therapeutic assembly 100 may increase or decrease the amount of energy delivered based on the difference between the temperature and the low threshold or high threshold, respectively.
  • the increase or decrease of the amount of energy delivered may be directly proportional to the magnitude of the difference between the temperature and the low threshold or high threshold, respectively.
  • the therapeutic assembly 100 may continue to monitor, detect, obtain and/or determine the temperature at the treatment site to determine whether further adjustments to the delivery of the energy may or may not be warranted. In some implementations, the therapeutic assembly 100 may not continue to monitor, measure, obtain and/or determine the temperature after the increase or decrease of the amount of energy that is delivered to the treatment site.

Abstract

L'invention concerne des procédés, des systèmes, des dispositifs, des ensembles et des appareils pour la dénervation rénale. L'ensemble thérapeutique comprend un premier élément d'apport d'énergie conçu pour apporter de l'énergie à un site de traitement. L'ensemble thérapeutique comprend un premier capteur couplé au premier élément d'apport d'énergie. Le premier capteur est conçu pour mesurer une première température du premier élément d'apport d'énergie. L'ensemble thérapeutique comprend un processeur couplé au premier capteur et au premier élément d'apport d'énergie. Le processeur est configuré pour augmenter l'apport d'énergie au site de traitement lorsque la première température est inférieure ou égale à une première température seuil, et ajuster l'apport d'énergie au site de traitement lorsque la première température est supérieure ou égale à une seconde température seuil.
EP20811201.1A 2019-10-31 2020-10-28 Modulation de l'apport d'énergie de dénervation rénale Pending EP4051147A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962928844P 2019-10-31 2019-10-31
PCT/US2020/057767 WO2021086984A1 (fr) 2019-10-31 2020-10-28 Modulation de l'apport d'énergie de dénervation rénale

Publications (1)

Publication Number Publication Date
EP4051147A1 true EP4051147A1 (fr) 2022-09-07

Family

ID=73498327

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20811201.1A Pending EP4051147A1 (fr) 2019-10-31 2020-10-28 Modulation de l'apport d'énergie de dénervation rénale

Country Status (3)

Country Link
EP (1) EP4051147A1 (fr)
CN (1) CN114901181A (fr)
WO (1) WO2021086984A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105056408B (zh) * 2006-06-28 2018-09-25 美敦力Af卢森堡公司 用于热诱导的肾神经调制的系统
US10285751B2 (en) * 2015-10-16 2019-05-14 Biosense Webster (Israel) Ltd. System and method for controlling catheter power based on renal ablation response
US11478298B2 (en) * 2018-01-24 2022-10-25 Medtronic Ardian Luxembourg S.A.R.L. Controlled irrigation for neuromodulation systems and associated methods

Also Published As

Publication number Publication date
WO2021086984A1 (fr) 2021-05-06
CN114901181A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
US11801085B2 (en) Devices for thermally-induced renal neuromodulation
US10350005B2 (en) Methods and apparatuses for remodeling tissue of or adjacent to a body passage
EP3060150B1 (fr) Procédés et systèmes de commande de courant
EP2034918A2 (fr) Systeme de catheter a base de haute frequence et procede d'ablation de tissus biologiques
WO2021086984A1 (fr) Modulation de l'apport d'énergie de dénervation rénale
WO2021086987A1 (fr) Ajustement d'apport d'énergie de dénervation rénale
WO2022180509A1 (fr) Dispositifs et méthodes pour déterminer une vasomotricité artériolaire rénale

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY